Abeona Therapeutics (NASDAQ:ABEO) Stock Rating Lowered by Cantor Fitzgerald

Abeona Therapeutics (NASDAQ:ABEO) was downgraded by investment analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued on Monday, MarketBeat reports. Cantor Fitzgerald also issued estimates for Abeona Therapeutics’ FY2020 earnings at ($1.10) EPS.

ABEO has been the subject of a number of other reports. ValuEngine raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Maxim Group restated a “buy” rating on shares of Abeona Therapeutics in a research note on Wednesday, May 1st. BidaskClub upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, June 17th. HC Wainwright started coverage on Abeona Therapeutics in a research note on Monday. They issued a “buy” rating and a $15.00 target price for the company. Finally, Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 30th. Six equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Abeona Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $19.67.

Shares of ABEO stock opened at $2.17 on Monday. The business’s 50 day simple moving average is $3.54 and its 200 day simple moving average is $6.08. Abeona Therapeutics has a one year low of $2.12 and a one year high of $15.65. The stock has a market capitalization of $117.86 million, a PE ratio of -1.82 and a beta of 1.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.54 and a quick ratio of 3.35.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.13). Abeona Therapeutics had a negative net margin of 960.91% and a negative return on equity of 59.99%. As a group, research analysts expect that Abeona Therapeutics will post -1.74 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in shares of Abeona Therapeutics by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 341,206 shares of the biopharmaceutical company’s stock valued at $2,436,000 after purchasing an additional 6,826 shares in the last quarter. Bank of America Corp DE increased its stake in Abeona Therapeutics by 440.5% in the 4th quarter. Bank of America Corp DE now owns 26,689 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 21,751 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in Abeona Therapeutics by 247.2% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,194 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 7,258 shares during the period. Nisa Investment Advisors LLC increased its stake in Abeona Therapeutics by 36.1% in the 1st quarter. Nisa Investment Advisors LLC now owns 37,700 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 10,000 shares during the period. Finally, BNP Paribas Arbitrage SA increased its stake in Abeona Therapeutics by 21,590.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,507 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 6,477 shares during the period. 63.32% of the stock is currently owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Recommended Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit